NASDAQ · Biotechnology · USD

DBV Technologies S.A. (DBVT) Stock Analysis

DBV Technologies S.A. (DBVT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DBVT

$13.47

−$0.23 (−1.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DBVT with… →

DBVT Key Statistics

As of Sep 4, 2026

Trading

Open: $13.42
Previous Close: $13.70
Day's Range: 13.30–13.58
52-Week Range: 8.70–26.19
Volume: 43.10K
Beta: −0.23

Valuation

Market Cap: $846.53M
P/E Ratio: unprofitable
P/S ratio: 168.10
EPS (ttm): −3.43

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$146.95M
Profit margin: 0.00%
Shares Outstanding: 62.85M
1-Year Return: +46.10%

Dividend and dates

Earnings Date: October 28, 2026
Avg Volume: 298.47K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DBVT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−75.51%+520.39%−29.73%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−29.73%
2025	+520.39%
2024	+62.12%
2023	−37.71%
2022	−4.38%
2021	−38.93%
2020	−75.51%
2019	+66.67%
2018	−73.90%
2017	−29.97%
2016 (partial year)	+4.15%

As of September 4, 2026.

DBVT Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$146.95M	—
2024	$0.00	−$113.92M	—
2023	$0.00	−$72.73M	—
2022	$0.00	−$96.27M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$147.05M	−$146.95M	—
2024	$0.00	—	−$116.59M	−$113.92M	—
2023	$0.00	—	−$76.43M	−$72.73M	—
2022	$0.00	—	−$96.63M	−$96.27M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DBVT Valuation vs Biotechnology Median

Median of 656 stocks

Metric	DBVT	Biotechnology median	vs median
P/S ratio	168.10	15.26	11.0x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

DBV Technologies S.A. (DBVT) is capitalised at $846.53M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 170.

Over the past 52 weeks the price has ranged from $8.70 to $26.19. The most recent close on file for DBVT is $13.47, dated September 4, 2026. That is −$0.23 (−1.68%) against the previous close. The latest close sits 54.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $146.95M. Profit margin runs at 0%. Trailing earnings per share are −3.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 168.1 times revenue. On price-to-sales that is 11 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +46.10%. Across 10 years the annualized return works out at −15.06%. The reported beta is −0.24. Annualized volatility over the trailing 10 years is 190.02%.

Growth & Income

No dividend is on file for DBVT.

2026 is still running; the price is −29.73% year to date. Across the complete calendar years on file, 2025 returned +520.39% and 2020 returned −75.51%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

DBV Technologies S.A. (DBVT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
DBV Technologies S.A.	DBVT	$846.53M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. DBV Technologies S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Visit website →